<?xml version="1.0" encoding="UTF-8"?>
<p id="para290">Once we have a good idea of what works, the hard part will be actually getting it to people. “The rate-limiting step will be manufacturing capability, not science. We want these drugs to be widely available, which means producing hundreds of millions of doses,” says Jeff Chertack, a spokesperson at the Bill &amp; Melinda Gates Foundation. Last month, the organisation launched an endeavour called the 
 <ext-link ext-link-type="uri" xlink:href="https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/03/COVID-19-Therapeutics-Accelerator" id="interrefs230" xmlns:xlink="http://www.w3.org/1999/xlink">Covid-19 Therapeutics Accelerator</ext-link>, which will contribute up to $125 million to speed up drug development from its earliest stages through to manufacturing and distribution. Chertack says its emphasis on all steps in the process is a deliberate strategy to ensure drugs are priced so that people who need them will be able to get them, regardless of income.
</p>
